Beyond Equity: When Should Life Sciences Companies Consider Convertible Debt?

Beyond Equity: When Should Life Sciences Companies Consider Convertible Debt?

Webinar CLE

On December 14, partners Craig Hilts, Erika Robinson and Dino Wu, alongside J. Wood Capital Advisors Founder & CEO Jason Wood and Managing Director Alton Lo, will present an overview of convertible debt transactions, dilution protection mechanisms and recent market trends in the life sciences industry.

As life sciences companies mature and advance towards commercialization of a product, they often consider issuing a convertible bond as a means of raising less dilutive capital. Current market conditions are very strong for issuers and companies have been able to raise capital at attractive pricing. Panelists will provide guidance to life sciences companies who may be considering whether and when a convertible bond financing might be appropriate and will discuss keys for successfully structuring and executing a convertible bond financing.

During the webinar, participants will have the opportunity to contribute questions online. CLE credit will be offered.

View the webinar recording.*

*CLE credit is not available for those who watch webinar recordings.


Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.